IRIDEX Corporation — FY 2015 Form 10-K
Business context and reporting period
IRIDEX develops and sells ophthalmic laser consoles, delivery devices, consumables, and related services for sight-threatening eye diseases. Its strategy centers on ophthalmology and expanding adoption of MicroPulse technology. The filing covers the fiscal year ended January 2, 2016 (52 weeks), with comparisons to FY 2014 (53 weeks) and FY 2013. It is an annual report, not a standalone fourth-quarter report; separate Q4 results are not clearly provided in the filing text.
Key financial metrics
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $41.757 million | $42.814 million |
| Gross profit / gross margin | $19.953 million / 47.8% | $21.405 million / 50.0% |
| Operating income | $0.288 million | $2.587 million |
| Net income | $0.474 million | $10.038 million |
| Basic / diluted earnings per share | $0.05 / $0.05 | $1.01 / $0.97 |
| Cash from operating activities | $(0.593) million | $4.014 million |
| Cash and cash equivalents at year-end | $9.995 million | $13.303 million |
| Working capital / debt | $23.3 million / none | $25.9 million / none |
FY 2015 revenue included $10.2 million of U.S. system sales, $11.6 million of international system sales, and $20.0 million of recurring revenue. International sales were 42.6% of total revenue. The company reported $5.2 million of R&D expense. Investing activities used $1.298 million, including $0.875 million of capital expenditures and $0.423 million of earn-out payments; financing activities used $1.417 million. Cash declined by $3.308 million during the year.
Material changes versus comparable periods
- Revenue fell about 2.5% from FY 2014. International system sales decreased $1.9 million, partly offset by higher U.S. system sales and recurring revenue, including demand for Cyclo G6 disposable MP3 probes.
- Management attributed weaker sales to production and quality problems that reduced shipments, especially to international distributors, during the second and third quarters. A stronger U.S. dollar also weighed on international competitiveness.
- Gross margin fell 2.2 percentage points, reflecting introductory Cyclo G6 pricing, sales mix, and lower manufacturing overhead absorption.
- Operating income declined to $0.288 million as revenue and gross profit decreased while R&D and sales and marketing spending increased.
- FY 2014 net income included an $8.7 million income-tax benefit, principally from releasing most of the deferred-tax valuation allowance. Accordingly, the FY 2014 net-income comparison is not representative of operating performance alone.
Outlook, risks, contingencies, and unusual items
- Management’s stated goal is continued profitability and profitable growth through MicroPulse adoption, product development, and recurring revenue. The filing provides no numerical revenue or earnings guidance. Management said cash and expected operating cash flows should fund operations for the next 12 months.
- Production and quality execution are immediate risks: the company disclosed recent manufacturing difficulties, shipment reductions, and added spending to address them. Continued problems could constrain revenue, raise costs, or damage customer relationships.
- Other material risks include reliance on sole- or limited-source component suppliers; international distributor performance and foreign-exchange effects on price competitiveness; intense device and pharmaceutical competition; regulatory clearances and CE certification; and changes in reimbursement or healthcare policy.
- Liquidity remained positive, but operating cash flow was negative and inventory rose from $9.1 million to $11.1 million. The company had no debt. It also had an outstanding $1.1 million authorization under its share repurchase program.
- Contractual obligations include operating lease payments of $3.210 million. The filing’s obligations table reports $11.671 million of supplier commitments, while a note separately presents $14.881 million as contract manufacturing and supply commitments; investors should clarify the apparent difference in presentation.
- The company reported $8.985 million of net deferred tax assets and an $0.806 million valuation allowance at year-end; realization depends on future taxable income. The company also reported $0.937 million of unrecognized tax benefits.
- Ordinary-course legal matters were not expected by management to have a material adverse effect. The filing reports no off-balance-sheet arrangements. Auditors issued an unqualified opinion on the financial statements; management concluded internal controls were effective, but the auditor did not attest to internal control effectiveness.
Important facts for investors to verify
- Whether manufacturing and quality issues were resolved and shipment levels recovered, particularly internationally.
- Whether Cyclo G6 adoption and recurring consumables revenue can offset weaker system sales while supporting gross margins.
- Whether inventory and receivables convert to cash and operating cash flow returns to positive levels.
- Whether deferred tax assets are realizable under the company’s future profitability assumptions.
- The scope and timing of supplier commitments, including the difference between the amounts presented in the obligations table and the commitments note.